Dr. Bard Geesaman began working with MPM in 2001 as part of the management team for the portfolio company Elixir Pharmaceuticals. In 2006 he became a venture partner at MPM and co-founded Solasia, a specialty pharmaceutical company in Asia developing oncology products. Prior to working at MPM, Dr. Geesaman was a General Partner at F2 Ventures, a U.K. based investment firm where he managed the private investments. Dr. Geesaman received his Ph.D. in systems biology from M.I.T., his M.D. from Harvard Medical School, and his B.S. in neurobiology from U.C. Berkeley. He is board certified in internal medicine and did his residency at Massachusetts General Hospital.